Search Result

Results for "

HCC (hepatocellular carcinoma)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADAMTS (1) Akt (2) Anaplastic lymphoma kinase (ALK) (2) Antibiotic (1) Apoptosis (24) Arf Family GTPase (1) Autophagy (3) Bacterial (2) Bcl-2 Family (2) BCL6 (4) c-Met/HGFR (4) CaMK (1) Caspase (4) DNA/RNA Synthesis (3) Drug Metabolite (1) Endogenous Metabolite (15) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (1) Ferroptosis (1) FGFR (4) Fluorescent Dye (1) Fungal (1) Glutaminase (2) Glycoprotein VI (1) HBV (1) HCV (2) HDAC (4) Hedgehog (1) Histone Acetyltransferase (1) IFNAR (1) iGluR (2) Interleukin Related (5) JNK (1) Keap1-Nrf2 (1) Liposome (3) MicroRNA (1) MMP (1) Na+/K+ ATPase (1) NF-κB (2) p38 MAPK (3) p62 (1) PI3K (1) PIN1 (1) PKA (1) PPAR (1) PROTACs (2) Pyruvate Kinase (1) RAR/RXR (2) Reactive Oxygen Species (4) SARS-CoV (1) SphK (2) STAT (6) Survivin (1) TGF-β Receptor (2) TNF Receptor (1) Topoisomerase (1) Tyrosinase (2) ULK (1) VEGFR (1) Wnt (2) YAP (1) β-catenin (1)
By Research Areas:	Cancer (65) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (2) Metabolic Disease (7) Neurological Disease (3)
Oligonucleotides:	Cholesterol (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2591

Isocorydine	Endogenous Metabolite	Cancer
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-W013514

2-Acetamidofluorene	DNA/RNA Synthesis	Cancer
2-Acetamidofluorene is a potent carcinogenan. 2-Acetamidofluorene is can be used fot induction of hepatocellular carcinoma (HCC) and multiple primary tumours .

HY-19832

SC66 5 Publications Verification	Akt Apoptosis	Cancer
SC66 is an Akt inhibitor, reduces cell viability in a dose- and time-dependent manner, inhibits colony formation and induces apoptosis in hepatocellular carcinoma (HCC) cells.

HY-141813

Autophagy-IN-C1	Autophagy	Cancer
Autophagy-IN-C1 not only induces apoptosis but also blocks autophagy in hepatocellular carcinoma (HCC) cells.

HY-151461

CHNQD-01255	Arf Family GTPase	Cancer
CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy .

HY-N11429

Glycochenodeoxycholic acid 3-glucuronide	Endogenous Metabolite	Metabolic Disease Cancer
Glycochenodeoxycholic acid 3-glucuronide is a type of steroid glucuronide and a plasma metabolite that can be used in the research of biomarkers for diabetes and hepatocellular carcinoma (HCC) .

HY-D2312

Mito-Rh-S	Fluorescent Dye Ferroptosis	Cancer
Mito-Rh-S is a ratiometric near-infrared (NIR) fluorescent probe that detects the fluctuation of mitochondrial HClO levels during ferroptosis in hepatocellular carcinoma (HCC) .

HY-161854

LASSBio-1911	HDAC	Cancer
LASSBio-1911 is a potent inhibitor of HDAC6. LASSBio-1911 shows antitumor in hepatocellular carcinoma (HCC) cells with minimal on normal cells .

HY-N2591A

Isocorydine hydrochloride	Endogenous Metabolite	Cancer
Isocorydine hydrochloride is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine hydrochloride combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-121799

Taurohyocholic acid THCA	Endogenous Metabolite	Cancer
Taurohyocholic acid is a taurine-conjugated hyocholic acid. Taurohyocholic acid is predictor of the efficacy of tyrosine kinase inhibitors combined withPD-1 inhibitors in hepatocellular carcinoma (HCC) .

HY-121799A

Taurohyocholic acid sodium salt THCA sodium salt	Endogenous Metabolite	Others
Taurohyocholic acid (THCA) sodium salt is a taurine-conjugated hyocholic acid. Taurohyocholic acid sodium salt is predictor of the efficacy of tyrosine kinase inhibitors combined withPD-1 inhibitors in hepatocellular carcinoma (HCC) .

HY-N7507A

Sempervirine nitrate	Wnt β-catenin	Cancer
Sempervirine is an alkaloid derived from Gelsemium elegans Benth.. Sempervirine inhibits the proliferation of hepatocellular carcinoma (HCC) cells and induces apoptosis by regulating Wnt/β-catenin pathway .

HY-121160

Amiprilose SM1213; Therafectin	Bacterial	Infection Cancer
Amiprilose (SM1213; Therafectin) is a potent inhibitor against Hepatocellular carcinoma (HCC). Amiprilose induces lymphokine-induced macrophage activation directly to kill Listeria monocytogenes .

HY-173387

4F-Docetaxel 4FDT	Others	Cancer
4F-Docetaxel (4FDT) is a fluorinated docetaxel analog. 4F-Docetaxel has anti-hepatoma activity and can be used for research of hepatocellular carcinoma (HCC) .

HY-N4168B

Methyl chlorogenate	Others	Cancer
Methyl chlorogenate is an antioxidant, and has radical scavenging activity. Methyl chlorogenate is an anti-inflammatory agent. Methyl chlorogenate also inhibits hepatocellular carcinoma (HCC) cell proliferation and metastasis .

HY-146504

Topoisomerase I/II inhibitor 3	Topoisomerase PI3K Apoptosis Reactive Oxygen Species	Cancer
Topoisomerase I/II inhibitor 3 (compound 7) is a potent topoisomerase I (Topo I) and II (Topo II) dual inhibitor. Topoisomerase I/II inhibitor 3 can inhibit cell proliferation, invasion and migration, and induce apoptosis by inhibiting PI3K/Akt/mTOR signaling pathway. Topoisomerase I/II inhibitor 3 can be used for liver cancer research .

HY-172394

ZSNI-21	HDAC ADAMTS	Cancer
ZSNI-21 is a dual inhibitor of ADAM17 and HDAC2. ZSNI-21 effectively inhibits the proliferation of Bel-7402 cells and demonstrates significant anti-metastatic capabilities against HCC-LM3 cells. ZSNI-21 is promising for research of hepatocellular carcinoma (HCC) .

HY-172499

DSPE-PEG1000-SP94	Liposome	Cancer
DSPE-PEG1000-SP94 is a PEG compound which composed of DSPE and a cell-penetrating peptide (SP94). SP94 shows specific binding to hepatocellular carcinoma (HCC) cells .

HY-172501

DSPE-PEG5000-SP94	Liposome	Cancer
DSPE-PEG5000-SP94 is a PEG compound which composed of DSPE and a cell-penetrating peptide (SP94). SP94 shows specific binding to hepatocellular carcinoma (HCC) cells .

HY-168872

API32	PIN1	Cancer
API32 is a potent Pin1 inhibitor. API32 interactes with the Pin1 PPIase domain. API32 inhibits cell proliferation and migration. API32 has the potential for the research of hepatocellular carcinoma (HCC) .

HY-172500

DSPE-PEG2000-SP94	Liposome	Cancer
DSPE-PEG2000-SP94 is a PEG compound which composed of DSPE and a cell-penetrating peptide (SP94). SP94 shows specific binding to hepatocellular carcinoma (HCC) cells .

HY-147187

MNK8	STAT Apoptosis Bcl-2 Family Survivin	Cancer
MNK8 is a potent STAT3 (signal transducer and activator of transcription 3) inhibitor. MNK8 inhibits STAT3 activation and reduced its DNA binding ability. MNK8 shows good growth inhibition against hepatocellular carcinoma (HCC) cells. MNK8 induces apoptosis in HCC cells. MNK8 reduces prosurvival proteins expression and migration/invasion of HCC cells .

HY-161617

LASSBio-2052	DNA/RNA Synthesis Apoptosis	Cancer
LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC₅₀ of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells .

HY-150072

DS89002333	PKA	Cancer
DS89002333 is an orally active and potent PRKACA inhibitor, with an IC₅₀ of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC) .

HY-P99353

Ascrinvacumab 2 Publications Verification Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962	Anaplastic lymphoma kinase (ALK)	Cancer
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a K_d value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .

HY-160765

WNTinib APS-8-100-2	Wnt Apoptosis	Cancer
WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation .

HY-132177

α-L-Fucosidase, Microorganism 1 Publications Verification EC 3.2.1.51; FUC	Endogenous Metabolite	Cancer
α-L-Fucosidase, Microorganism (EC 3.2.1.51) is an enzyme that catalyzes the chemical reaction. Serum activity of α-L-Fucosidase, Microorganism, a lysosomal enzyme present in all mammalian cells, has been proposed as a marker of hepatocellular carcinoma (HCC) .

HY-N2334

Glycochenodeoxycholic acid 4 Publications Verification Chenodeoxycholylglycine	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-N2334A

Glycochenodeoxycholic acid sodium salt 4 Publications Verification Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-N6623

Malvidin-3-galactoside chloride	Apoptosis Endogenous Metabolite Reactive Oxygen Species	Cancer
Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and apoptosis. Malvidin-3-galactoside chloride inhibits the production and accumulation of ROS. Malvidin-3-galactoside chloride has anti-tumor function .

HY-100492

Fisogatinib 2 Publications Verification BLU-554	FGFR	Cancer
Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling .

HY-149063

Antitumor agent-92	Apoptosis	Cancer
Antitumor agent-92, an Icaritin (HY-N0678) derivative, causes arrest at the G0/G1 phase in the cell cycle and induces cell apoptosis. Antitumor agent-92 has the potential for hepatocellular carcinoma (HCC) research .

HY-155248

HL23	HDAC	Cancer
HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221) .

HY-13267

Droxinostat 3 Publications Verification NS 41080	HDAC Apoptosis	Cancer
Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC₅₀ values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC) .

HY-137506

XST-14 1 Publications Verification	ULK p38 MAPK TGF-β Receptor Anaplastic lymphoma kinase (ALK) CaMK Apoptosis	Cancer
XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC₅₀ of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects .

HY-149475

VEGFR-2-IN-33	VEGFR	Cancer
VEGFR-2-IN-33 (Compound 4d) is a VEGFR inhibitor (IC₅₀: 61.04 nM). VEGFR-2-IN-33 inhibits HepG2 cell proliferation with an IC₅₀ of 4.31 nM. VEGFR-2-IN-33 can be used for research of hepatocellular carcinoma (HCC) .

HY-15897

LDN-212854 1 Publications Verification	TGF-β Receptor	Cancer
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC₅₀: 1.3 nM). LDN-212854 also inhibits ALK1 (IC₅₀: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) .

HY-101519

BETd-260 3 Publications Verification ZBC 260	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
BETd-260 (ZBC 260) is a PROTAC connected by ligands for Cereblon and BET, with as low as 30 pM against BRD4 protein in RS4;11 leukemia cell line . BETd-260 potently suppresses cell viability and robustly induces apoptosis in hepatocellular carcinoma (HCC) cells .

HY-P99013

Codrituzumab 1 Publications Verification GC33; RO5137382	Glycoprotein VI	Cancer
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (K_d of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .

HY-W015309

Decanoic acid 2 Publications Verification	iGluR Tyrosinase c-Met/HGFR Glutaminase Endogenous Metabolite	Neurological Disease Metabolic Disease Cancer
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-N2334R

Glycochenodeoxycholic acid (Standard) Chenodeoxycholylglycine (Standard)	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid (Standard) is the analytical standard of Glycochenodeoxycholic acid. This product is intended for research and analytical applications. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC)[1][2][3][4].

HY-138813R

N-Desethyl Sunitinib (hydrochloride) (Standard)	Drug Metabolite	Cancer
Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-N2334AR

Glycochenodeoxycholic acid sodium salt (Standard)	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-150538

STAT3-IN-12	STAT Apoptosis	Cancer
STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma .

HY-111226

GSK5182 2 Publications Verification	Estrogen Receptor/ERR Reactive Oxygen Species	Cardiovascular Disease Cancer
GSK5182 is a highly selective and orally active inverse agonist of estrogen-related receptor γ (ERRγ) with an IC₅₀ of 79 nM. GSK5182 does not interact with other nuclear receptors, including ERRα or ERα. GSK5182 also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma (HCC) .

HY-115902

FGFR4-IN-7	FGFR Apoptosis	Cancer
FGFR4-IN-7 (Compound C3) is a covalent reversible FGFR4 inhibitor with an IC₅₀ value of 0.42 μM. FGFR4-IN-7 induces apoptosis via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC) .

HY-162679

c-Met degrader-1	c-Met/HGFR Apoptosis	Cancer
c-Met degrader-1 (Compound H11) is an orally active c-Met degrader (through the ubiquitin proteasome system). c-Met degrader-1 has anti-hepatocellular carcinoma activity (HCC) and inhibits tumor growth in MHCC97H xenografts. c-Met degrader-1 inhibits HCC cell growth, arrests cell cycle, and induces apoptosis. c-Met degrader-1 may overcome resistance to type Ib inhibitors .

HY-N7073

Silymarin 5 Publications Verification	SARS-CoV	Infection Neurological Disease Inflammation/Immunology Cancer
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (M ^pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .

HY-152169

BIHC	Interleukin Related Apoptosis TNF Receptor IFNAR NF-κB Bcl-2 Family	Inflammation/Immunology
BIHC is a TNF blocker with anti-inflammatory activity. BIHC can significantly inhibit the proliferation of hepatocellular carcinoma (HCC) cells and exhibits potent cytotoxicity against the HepG2 cell line, capable of inducing cell apoptosis , while demonstrating relatively low toxicity towards normal hepatocytes. Additionally, BIHC can be used for research on inflammatory bowel disease (IBD) .

HY-130173

Bafilomycin C1 1 Publications Verification	Bacterial Fungal Na+/K+ ATPase Apoptosis Antibiotic	Infection Cancer
Bafilomycin C1 is a macrolide antibiotic isolated from Streptomyces sp. Bafilomycin C1 is a potent, specific and reversible inhibitor of vacuolar-type H ⁺-ATPases (V-ATPases). Bafilomycin C1 inhibits growth of gram-positive bacteria and fungi . Bafilomycin C1 induces cell apoptosis and can be used for the study of hepatocellular carcinoma (HCC) .

Cat. No.	Product Name

HY-L101

Anti-Liver Cancer Compound Library

2,284 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 2,284 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-D2312

Mito-Rh-S	Fluorescent Dyes/Probes
Mito-Rh-S is a ratiometric near-infrared (NIR) fluorescent probe that detects the fluctuation of mitochondrial HClO levels during ferroptosis in hepatocellular carcinoma (HCC) .

Cat. No.	Product Name	Type

HY-W001925

7-Methoxy-1-tetralone

Biochemical Assay Reagents

7-Methoxy-1-tetralone is a potent antitumor agent. 7-Methoxy-1-tetralone inhibits cancer cell proliferation and migration, and induces hepatocellular carcinoma cell (HCC) apoptosis. 7-Methoxy-1-tetralone decreased the protein levels of NF-κB, matrix metallopeptidase 2 (MMP2)/MMP9, and p-AKT. 7-Methoxy-1-tetralone showed antitumor activity in nude mice and had no effect on body weight and liver, spleen and organ index .

HY-172499

DSPE-PEG1000-SP94	Drug Delivery
DSPE-PEG1000-SP94 is a PEG compound which composed of DSPE and a cell-penetrating peptide (SP94). SP94 shows specific binding to hepatocellular carcinoma (HCC) cells .

HY-172501

DSPE-PEG5000-SP94	Drug Delivery
DSPE-PEG5000-SP94 is a PEG compound which composed of DSPE and a cell-penetrating peptide (SP94). SP94 shows specific binding to hepatocellular carcinoma (HCC) cells .

HY-172500

DSPE-PEG2000-SP94	Drug Delivery
DSPE-PEG2000-SP94 is a PEG compound which composed of DSPE and a cell-penetrating peptide (SP94). SP94 shows specific binding to hepatocellular carcinoma (HCC) cells .

Cat. No.	Product Name	Target	Research Area

HY-P10553

ARF(26–44), cell-permeable	Apoptosis	Cancer
ARF(26–44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable can be used in research on tumor therapy .

Cat. No.	Product Name	Target	Research Area

HY-P99353

Ascrinvacumab 2 Publications Verification Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962	Anaplastic lymphoma kinase (ALK)	Cancer
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a K_d value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .

HY-P99013

Codrituzumab 1 Publications Verification GC33; RO5137382	Glycoprotein VI	Cancer
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (K_d of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .

Cat. No.	Product Name		Classification

HY-121799A

Taurohyocholic acid sodium salt THCA sodium salt		Cholesterol
Taurohyocholic acid (THCA) sodium salt is a taurine-conjugated hyocholic acid. Taurohyocholic acid sodium salt is predictor of the efficacy of tyrosine kinase inhibitors combined withPD-1 inhibitors in hepatocellular carcinoma (HCC) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HCC (hepatocellular carcinoma)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products